Clinical trials: Pulmonary Hypertension
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03012646
- Testing
- Inhaled Treprostinil
- Sponsor
- United Therapeutics
Persistent Pulmonary Hypertension of the Newborn
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).
- Trial name
- NCT02261883
- Testing
- IV Remodulin
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Interstitial Lung Disease
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
- Trial name
- NCT07234032
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 11 sites in United States, Czechia and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Heart Diseases, Hypertension, Pulmonary
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery.
- Trial name
- NCT00458276
- Testing
- tezosentan
- Where
- 33 sites in United States, Austria and 12 more
- Volunteers
- 274 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Hypertension
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
The primary objective of this study was to evaluate the safety and efficacy of ambrisentan in a broad population of participants with pulmonary hypertension (PH).
- Trial name
- NCT00380068
- Testing
- Ambrisentan
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
Hypertension, Pulmonary
A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries
The aim of the registry is the assessment of the diagnosis and treatment of CTEPH (Chronic Thromboembolic Pulmonary Hypertension) in EMEA (Europe/Middle East/Africa) countries.
- Trial name
- EMEA CTEPH (NCT02637050)
- Testing
- Standard of care
- Where
- 6 sites in Kazakhstan, Kyrgyzstan and 4 more
- Volunteers
- 231 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in…
- Trial name
- ARTISAN (NCT05203510)
- Testing
- Parenteral Treprostinil, Oral Treprostinil
- Where
- 28 sites in United States
- Volunteers
- 52 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
Local, prospective, multicenter, non-comparative, non-interventional, observational study. It is planed to assess compliance of patients with PH (pulmonary hypertension) with the physician's recommendation in real practice.
- Trial name
- IVENT (NCT01971450)
- Testing
- Iloprost (Ventavis, BAYQ6256)
- Where
- Russia
- Volunteers
- 89 people
- Sponsor
- Bayer
Cardiovascular Diseases, Right Heart Failure
Repository of Phase Signals for Pulmonary Hypertension Algorithm Development
This study is designed as a repository study to collect resting cardiac phase signals and subject meta data from eligible subjects using the Phase Signal Recorder (PSR) prior to Right Heart Cath (RHC).
- Conditions
- Cardiovascular Diseases, Right Heart Failure, Cardiac Disease
- Trial name
- IDENTIFY - PH (NCT04031989)
- Testing
- CorVista Capture
- Where
- 17 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Analytics For Life
Hypertension, Pulmonary
A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study
The purpose of this study is to assess the long-term safety of selexipag while providing continued selexipag treatment for participants who were previously enrolled in an Actelion-sponsored study with selexipag and who derived…
- Trial name
- SOMBRERO (NCT04565990)
- Testing
- Selexipag
- Where
- 13 sites in Belarus, India and 4 more
- Volunteers
- 43 people
- Sponsor
- Actelion
COPD, Pulmonary Hypertension
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of long term iNO administrationusing the…
- Conditions
- COPD, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03135860
- Testing
- Inhaled Nitric Oxide 30mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bellerophon
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
Berlin Cures develops BC 007 to treat patients suffering from diseases (chronic heart failure, pulmonary hypertension, chronic fatigue syndrome etc.) which are associated with functional autoantibodies (AAB) directed against…
- Trial name
- NCT02955420
- Testing
- BC 007, NaCl 0.9 %
- Where
- Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Berlin Cures GmbH
Pulmonary Arterial Hypertension
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
A sub-study to the TDE-PH-304 protocol to assess the pharmacokinetics of patients transitioning from a twice daily dosing regimen of oral treprostinil to a three times daily dosing regimen.
- Trial name
- NCT01934582
- Testing
- UT-15C SR, treprostinil diethanolamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- United Therapeutics
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
The endothelin receptor antagonist macitentan showed significant improvement compared with placebo in pulmonary vascular resistance (PVR) and 6-minute walking distance (6MWD) in inoperable CTEPH patients in the phase II MERIT-1…
- Trial name
- NCT03809650
- Testing
- macitentan 10 mg
- Where
- 23 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Actelion
Pulmonary Hypertension of Newborn
A Real-world Study of Nitric Oxide Generator and Delivery System
The study is aimed to observe the efficacy and safety of Nitric Oxide Generator and Delivery System in Pulmonary Hypertension of Newborn in real clinical settings.
- Trial name
- NCT05703191
- Testing
- Nitric Oxide Generator and Delivery System
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Novlead Inc.
Pulmonary Hypertension
Discovering Clinical Study Experiences of Patients With Pulmonary Hypertension
Taking part in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05918458
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
This is a multicenter, single-arm trial to evaluate the safety of the transition from Selexipag to Remodulin® then Oral Treprostinil in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT03016468
- Testing
- Parenteral Remodulin (treprostinil) injection, Oral Treprostinil
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
OPsumit USers Registry
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with…
- Trial name
- OPUS (NCT02126943)
- Testing
- Opsumit (macitentan)
- Where
- 146 sites in United States, Puerto Rico
- Volunteers
- 2,686 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
The purpose of this study is to evaluate how safe Opsynvi (macitentan/tadalafil fixed-dose combination) is in adult participants with pulmonary arterial hypertension under routine clinical practice in Korea.
- Trial name
- Opsynvi RMP (NCT07890285)
- Volunteers
- 333 people
- Sponsor
- Janssen Korea, Ltd., Korea